Emerging Clinical Trials and Future Therapeutic Strategies in Recurrent Endometrial Cancer

The panel surveys the clinical trial landscape and emerging therapeutic strategies for patients with recurrent endometrial cancer, particularly those who have progressed on frontline checkpoint inhibitor–based therapy. Dr. Thaker highlights multiple antibody-drug conjugate targets under active investigation, including folate receptor alpha, TROP2, and HER2, cautioning that sequencing questions across this class remain unanswered. She and Dr. Redfern also address the subset of mismatch repair–deficient patients who do not derive benefit from immunotherapy, emphasizing the importance of understanding resistance mechanisms. Data from GOG-3012 on post–checkpoint inhibitor sequencing strategies are briefly reviewed. The panel unanimously urges referring patients—especially those without access to clinical trials at their own institution—to academic centers with open studies, noting the remarkable expansion of trial opportunities in endometrial cancer compared with just 5 years prior.